Across TCGA pan-cancer cohorts, NOB1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NOB1 data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher NOB1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NOB1 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.
STAD, PRAD, and UCEC are the cancer types where NOB1 Mutation most reproducibly stratifies survival.